Matches 1 - 26 out of 26


Match Document Document Title
DE102017125888A1 New engineered T cell receptors and their use in immunotherapy  
The present invention relates to antigen-recognizing constructs against COL6A3 antigens. In particular, the invention provides novel engineered T cell receptor (TCR) based molecules which are...
DE102016115246C5 NEW T-CELL RECEPTORS AND THEIR USE IN IMMUNOTHERAPY  
The present invention relates to antigen-recognizing constructs against COL6A3 antigens. In particular, the invention provides new T cell receptor (TCR) based molecules that are selective and...
DE102016115246B3 NEW T-CELL RECEPTORS AND THEIR USE IN IMMUNOTHERAPY  
The present invention relates to antigen-recognizing constructs against COL6A3 antigens. In particular, the invention provides new T cell receptor (TCR) based molecules which are selective and...
DE112008003232T5 Antigen binding constructs  
An antigen-binding construct consisting of a protein backbone that is associated with one or more epitope binding domains, wherein the antigen-binding construct has at least two antigen binding...
DE10341812A1 Differentially expressed in tumors gene products and their use  
According to the invention were Tumor-associated gene products expressed and coding the for nucleic acids identified. The present invention relates to the therapy and Diagnosis of diseases in...
DE10259713A1 A method for expressing stabilization and improvement of specific effector function of single-chain antigen knower genetic constructs (scARC) and corresponding mutant MDM2 protein specific SCT-cell receptors  
The present invention relates to a process for preparing stabilized single chain antigen recognized genetic constructs (scARC), in which in addition to the conventional V1/2-Li-V2/1-C4/3-sc...
DE10109813A1 Tumor peptide antigen from human MDM2 proto-oncogene  
The invention relates to a universal tumour-associated oligopeptide, which is recognised by CD8-positive cytotoxic T-lymphocytes (CTL) as a peptide antigen and which causes a CTL-induced lysis...
DE10135996A1 Identifying metastatic tumor cells and screening for antitumor agents, comprises hybridization to specific cDNA sequences  
Identifying metastatic tumor cells (A) comprising testing them for hybridization to at least one cDNA sequence (I) not defined in the specification, or the derived complete gene, functional...
DE10043437A1 Use of trifunctional bispecific and trispecific antibodies for the treatment of malignant ascites  
The invention relates to the use of a pharmaceutical preparation, containing a trifunctional bispecific and/or trispecific antibody with the following properties: a) binding to a T-cell; b)...
DE10041342A1 Preparing vaccine against cancer, useful for treatment or prevention, comprises coupling antibody mimetopes,selected from a phage-display library, to macromolecular carrier  
Preparing a vaccine (A) against cancer, comprising conjugating one or more mimetopes of an antibody (Ab) to a macromolecular carrier (I), is new. The mimetopes are selected from a phage-display...
DE10018403A1 Preparing vaccine against cancer, useful for treatment or prevention, comprises coupling antibody mimetopes,selected from a phage-display library, to macromolecular carrier  
Preparing a vaccine (A) against cancer, comprising conjugating one or more mimetopes of an antibody (Ab) to a macromolecular carrier (I), is new. The mimetopes are selected from a phage-display...
DE19936563A1 Tumor associated antigen  
The invention relates to tumor-associated antigens, immunogenic peptides derived therefrom and the DNA molecules coding therefor as well as to their utilization in cancer immunotherapy.
DE19933237A1 A method for determining the proliferative activity of cells  
The invention relates to methods for determining the proliferation activity of cells by analyzing the concentration and/or the sub-cellular localization of the APC protein in samples and...
DE19919225A1 Tumor associated antigen  
The invention relates to a tumour-associated antigen, to immunogenic peptides derived therefrom, to DNA molecules that code for said peptides and to the use thereof in the immunotherapy of cancer.
DE19817557A1 Human nucleic acid sequences from Ovartumorgewebe  
The invention relates to human nucleic acid sequences - mRNA, cDNA, genome sequences - of ovarian tumour tissue, which code for gene products or parts of these products, and to their use. The...
DE19811194A1 New nucleic acid expressed at high level in normal prostatic tissue and encoded polypeptides, used to treat cancer and screen for therapeutic agents  
Nucleic acid sequences (A) that are expressed at high level in normal prostatic tissue and encode gene products or their fragments, are new. (A) is: (a) one of 64 sequences (all reproduced); (b)...
DE19811193A1 New nucleic acid expressed at high level in prostatic tumor tissue and encoded polypeptides, useful for treating cancer and screening for therapeutic agents  
Nucleic acid sequences (A) that are expressed at high level in prostatic tumor tissue and encode gene products or their fragments are new. (A) is: (a) one of 54 sequences (all reproduced), all...
DE19835633C1 Animal or human tumor cells which express immunoglobulins  
Animal or human tumor cells (A) expressing immunoglobulins (I) directed against antigens on antigen-presenting cells (APCs), but do not comprise parental tumor-derived immunoglobulins, are new....
DE19752855A1 Retroviral pseudotype vectors with modified surface envelope proteins and methods for their preparation for the selective gene transfer  
The invention relates to pseudo-type retroviral vectors with modified surface capsid proteins which are suitable for cell-specific transduction of a selected mammal cell type (cell targeting). The...
DE19605105A1 New probe for the early detection of epithelial dysplasia of the stratified squamous epithelium and for tumor diagnostics and tumor therapy of squamous  
The invention proposes a therapeutic or diagnostic agent including at least one substance containing at least one nucleic acid which hybridizes with a pax9 gene or a derivative thereof. The agent...
DE19531348A1 Antibodies having two or more specificities for the selective elimination of cells in vivo  
The invention concerns antibodies having two or more specificities detecting two different antigens localized on a tumour cell. The invention further concerns medicaments and diagnostic...
DE19507166C1 Antibodies specific for fusion polypeptide(s) contg. a histidine component  
The present invention concerns antibodies which are active against a fusion polypeptide comprising a histidine portion, a process for their preparation and their use.
DE4225569A1 New probe for tumor diagnosis or tumor therapy  
A therapeutical or diagnosing agent contains as active substance at least one nucleic acid which hybridises with a pax gene, or atleast a pax protein, or at least one antibody against a pax...
DE4224542A1 Monoclonal antibodies for diagnosis or therapy - directed against conjugate of MHC class I mol and peptide antigen  
Producing monoclonal antibodies directed against a conjugate of a major histocompatibility complex class I mol. (I) and a peptide antigen (II) comprises (a) isolating (I); (b) inserting a...
DE4205148A1 Monoclonal antibodies to C-KIT  
The invention concerns monoclonal antibodies against the human c-kit receptor which are obtainable from the DSM ACC 2007, DSM ACC 2008 and DSM ACC 2009 cell lines or can be bound to the c-kit...
DE4005630A1 Monoclonal antibodies against tumour-associated antigens - specifically MAB BW SCLC-1 and MAB BW SCLC-2, used in immune therapy and treatment and diagnosis of tumours  
The MAbs are derived from neuroectodermal tumours (e.g. small-celled lung carcinoma, SCLC), melanoma, neuroblastoma or cultures of cell lines of these tumours. The pred. antigens are derived from...

Matches 1 - 26 out of 26